UCB SA (UCBJF) (FY 2025) Earnings Call Highlights: Record Growth and Strategic Investments ... [Yahoo! Finance]
UCB SA UNSP/ADR (UCBJY)
NASDAQ:AMEX Investor Relations:
ucb.com/investors
Company Research
Source: Yahoo! Finance
This article first appeared on GuruFocus Net Sales Growth: +35% at constant trend. Revenue from Growth Drivers: EUR3.3 billion, more than double from last year. Bimekizumab Revenue: Over EUR2.2 billion in 2025. Adjusted Gross Profit: EUR6.1 billion, up 27%. Gross Margin: Improved to 79.2%. Operating Expenses: EUR3.7 billion, up 5%. Adjusted EBITDA: EUR2.6 billion, up 79%. EBITDA Margin: Increased by 10 percentage points to 34%. Core EPS: EUR9.99, doubling year on year. FINTEPLA Revenue: EUR427 million, 26% growth year-on-year. RYSTIGGO and ZILBRYSQ Revenue: Combined over EUR270 million. EVENITY Net Contribution: EUR632 million, 32% growth. CIMZIA Revenue: EUR1.95 billion, down 4%. BRIVIACT Revenue: EUR758 million, 11% growth. 2026 Revenue Guidance: High-single-digit to low-double-digit growth at constant exchange rates. 2026 EBITDA Guidance: High-single-digit to high-teens growth at constant exchange rates. Warning! GuruFocus has detected 9 Warning S
Show less
Read more
Impact Snapshot
Event Time:
UCBJY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UCBJY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UCBJY alerts
High impacting UCB SA UNSP/ADR news events
Weekly update
A roundup of the hottest topics
UCBJY
News
- UCB (UCBJY) was upgraded by Wolfe Research to "strong-buy".MarketBeat
- Sixth Annual Seizure Action Plan Awareness Week to Promote Seizure Preparedness Nationwide, Feb. 9-16, 2026PR Web
- UCB Canada remains dedicated to helping patients and working collaboratively with CDA-AMC following draft recommendation for (Pr)BIMZELX® for hidradenitis suppurativa (HS) [Yahoo! Finance]Yahoo! Finance
- PrBIMZELX® (bimekizumab injection) approved in Canada for treatment of moderate to severe hidradenitis suppurativa (HS) [Yahoo! Finance]Yahoo! Finance
- UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduced countable motor seizure frequency in CDKL5 deficiency disorderPR Newswire